Equities research analysts expect that Collegium Pharmaceutical Inc (NASDAQ:COLL) will announce $74.28 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Collegium Pharmaceutical’s earnings, with the lowest sales estimate coming in at $71.04 million and the highest estimate coming in at $78.53 million. Collegium Pharmaceutical reported sales of $10.79 million in the same quarter last year, which indicates a positive year-over-year growth rate of 588.4%. The company is expected to issue its next earnings results on Wednesday, March 6th.
On average, analysts expect that Collegium Pharmaceutical will report full year sales of $281.02 million for the current fiscal year, with estimates ranging from $278.03 million to $285.52 million. For the next year, analysts forecast that the company will report sales of $332.99 million, with estimates ranging from $325.78 million to $343.40 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.14). Collegium Pharmaceutical had a negative net margin of 30.13% and a negative return on equity of 70.06%. The company had revenue of $70.20 million during the quarter, compared to analyst estimates of $74.79 million. During the same period in the previous year, the firm posted ($0.45) earnings per share. The company’s revenue was up 485.0% compared to the same quarter last year.
NASDAQ:COLL traded down $0.62 during trading hours on Tuesday, reaching $19.06. The company had a trading volume of 493,743 shares, compared to its average volume of 503,608. The company has a current ratio of 0.78, a quick ratio of 0.75 and a debt-to-equity ratio of 4.17. The company has a market capitalization of $633.69 million, a PE ratio of -7.72 and a beta of 0.29. Collegium Pharmaceutical has a 1-year low of $13.70 and a 1-year high of $29.90.
In related news, Director Michael Thomas Heffernan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, November 15th. The stock was sold at an average price of $16.60, for a total transaction of $415,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 25.76% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of the business. Janus Henderson Group PLC grew its holdings in Collegium Pharmaceutical by 8.1% in the 3rd quarter. Janus Henderson Group PLC now owns 4,119,823 shares of the specialty pharmaceutical company’s stock valued at $60,726,000 after buying an additional 309,477 shares in the last quarter. Macquarie Group Ltd. grew its holdings in Collegium Pharmaceutical by 9.9% in the 2nd quarter. Macquarie Group Ltd. now owns 2,588,356 shares of the specialty pharmaceutical company’s stock valued at $61,732,000 after buying an additional 233,598 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Collegium Pharmaceutical by 7.0% during the 3rd quarter. BlackRock Inc. now owns 2,409,573 shares of the specialty pharmaceutical company’s stock worth $35,517,000 after purchasing an additional 157,300 shares during the period. Franklin Resources Inc. grew its holdings in shares of Collegium Pharmaceutical by 24.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,759,506 shares of the specialty pharmaceutical company’s stock worth $25,935,000 after purchasing an additional 347,064 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Collegium Pharmaceutical by 9.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,375,709 shares of the specialty pharmaceutical company’s stock worth $20,278,000 after purchasing an additional 113,038 shares during the period.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Featured Story: Short Selling – Explanation For Shorting Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.